How Does Smith & Nephew Company Work?

This division focuses on joint reconstruction, including hips and knees, as well as trauma and extremities. Key products like the JOURNEY II Total Knee System and the POLAR3 Total Hip Solution are central to its offerings in this segment.

This segment supports minimally invasive surgical procedures with innovative products. Examples include the REGENETEN Bioinductive Implant and the Q-FIX KNOTLESS All-Suture Anchor, enhancing surgical capabilities.

Smith & Nephew's operations are driven by robust research and development, with over 60% of its 2024 revenue growth attributed to products launched in the last five years. The company manages a global supply chain and distribution network, delivering products to over 100 countries.

A cornerstone of Smith & Nephew's competitive edge is its unwavering commitment to innovation. In 2024, over 60% of its underlying revenue growth was directly linked to products introduced within the preceding five years. The company has consistently expanded its product portfolio, launching nearly 50 new products over the last three years, with a robust pipeline anticipated for 2025.

The company has proactively addressed operational hurdles, including global supply chain disruptions and the impact of China's Volume-Based Procurement (VBP) program. These challenges have presented headwinds, particularly in the Orthopaedics and Sports Medicine Joint Repair sectors. Smith & Nephew's strategic response includes significant productivity enhancements, such as a nearly 9% reduction in its global workforce and the closure of four underperforming manufacturing facilities.

Recent product introductions have bolstered the company's market position. The CATALYSTEM Primary Hip System and the Q-FIX KNOTLESS All-Suture Anchor have been significant contributors to growth in the first half of 2025, underscoring the effectiveness of its new product development strategy.

Smith & Nephew's competitive advantages are multifaceted, encompassing strong brand recognition and technological leadership. The CORI Surgical System, with over 1,000 global installations by the end of 2024, including a robotic revision knee application, exemplifies this technological prowess. Furthermore, economies of scale across its global operations and continuous investment in robotic-assisted surgery and digital health solutions reinforce its durable competitive edge in the medical technology sector.

In 2024, Smith & Nephew secured an 11% share of the global knee implant market and a 9% share in the hip implant market. Its Advanced Wound Management division ranks as the second-largest globally by revenue, underscoring its strong market standing.

The company faces potential impacts from regulatory shifts, such as proposed Medicare reimbursement changes for skin substitutes, which could affect its Advanced Wound Management segment. Additionally, geopolitical factors like U.S. tariffs on Chinese imports are estimated to reduce 2025 profits by $15 million to $20 million.

Smith & Nephew's strategy is driven by its '12-Point Plan' and a focus on innovation, with over 20 product launches planned for 2025. The company anticipates absorbing tariff impacts within its current margin guidance and aims for continued margin expansion through efficiency improvements.

The company targets approximately 5% underlying revenue growth and a trading profit margin of 19.0% to 20.0% for 2025. A $500 million share buyback is planned for the second half of 2025, reflecting confidence in its cash flow and commitment to shareholders.